Pasar al contenido principal

Desarrollo de biosensores y química biológica en el descubrimiento de fármacos para enfermedades neurodegenerativas

RYC2019-027489-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanomedical research and development in Spain: improving the treatment of diseases from the nanoscale

  • Fernández, Paula
  • Pérez de la Lastra, C.
  • Tosat-Bitrian, Carlota
  • Bueso de Barrio, Jesús Alejandro
  • Thompson, Sebastian
  • Sot, Begoña
  • Salas, Gorka
  • Somoza, Álvaro
  • Espinosa, Ana
  • Castellanos, Milagros
  • Palomo, Valle
49 p.-7 fig.-9 tab., The new and unique possibilities that nanomaterials offer have greatly impacted biomedicine, from the treatment and diagnosis of diseases, to the specific and optimized delivery of therapeutic agents. Technological advances in the synthesis, characterization, standardization, and therapeutic performance of nanoparticles have enabled the approval of several nanomedicines and novel applications. Discoveries continue to rise exponentially in all disease areas, from cancer to neurodegenerative diseases. In Spain, there is a substantial net of researchers involved in the development of nanodiagnostics and nanomedicines. In this review, we summarize the state of the art of nanotechnology, focusing on nanoparticles, for the treatment of diseases in Spain (2017–2022), and give a perspective on the future trends and direction that nanomedicine research is taking., This work has been partially supported by MCIN/AEI /10.13039/501100011033 and European Union NextGenerationEU/PRTR (PID2021-128340OA-I00, PID2020-119352RB-I00, PID2021-127033OB-C21 and RTI2018-101050-J-I00), Comunidad de Madrid (S2022/BMD-7403 RENIM-CM and Talento program 2018-T1/IND-1005), European Union’s Horizon 2020 research and innovation programme (grant agreement No 685795), la Caixa Foundation LCF/PR/HA21/52350003, Asociación Española Contra el Cáncer IDEAS21989THOM, MCIN/AEI/10.13039/501100011033 and “ESF investing in your future” (RYC2019-027489-I, RYC2020-029282-I). CTB thanks Ministerio de Educación (FPU18/06310) for the predoctoral fellowship. IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centers of Excellence in R&D (MINECO, CEX2020-001039-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2020-001039-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Illuminating microtubule functions with small molecules: past, present and future of fluorescent tubulin-binding probes

  • París-Ogáyar R.
  • Lucena-Agell D
  • Altmann K.-H.
  • Palomo V.
  • Díaz J.F.
Developing tools for the real-time visualization of tubulin, microtubules, and their dynamics is essential for studying key cellular processes such as cell division, migration, and differentiation. In this context, fluorescent small-molecule probes that bind to distinct and specific sites on microtubules have significantly advanced our understanding of tubulin dynamics and functions. In addition, fluorescent probes targeting tubulin have enabled the development of high-throughput screening assays to identify novel anti-tubulin compounds. In this review, we present a comprehensive overview of currently available fluorescent molecules that bind to tubulin, detailing their chemical structures, binding sites, development strategies and relevance to the study of microtubule functions. We also explore future directions in this field and highlight key fluorescent probes that are still lacking. Developing these tools would enable the investigation of tubulin's diverse cellular roles in even greater depth and support the advancement of tubulin-targeted therapeutics, This work was partially funded by grants RYC2019-027489-I (VP), PID2021-128340OA-I00 (VP) and PID2022-136765OB-I00 (JFD) from the Ministerio de Ciencia e Innovación (MICIN) and FEDER as well as CNS2022-135852 (VP) from MCIN/AEI/ 10.13039/501100011033, FSE invierte en tu futuro, and the European Union NextGenerationEU/PRTR., Peer reviewed, Sin experimentacion animal ni uso de NAMs
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lighting Up Mislocalized Proteins: Quantum Dot Probes for Multiplexed Cytoplasm-Selective Cell Profiling in Neurodegeneration

  • Fernández-Gómez, Paula
  • Tosat-Bitrian, Carlota
  • Marugán, Tania
  • Fernández-Hernández, Laura
  • Cano, Alicia
  • Martinez-Mulero, Jose A.
  • López-Carbonero, Juan I.
  • Pignatelli, Jaime
  • Corrochano, Silvia
  • Palomo, Valle
Semiconductor quantum dots (QDs) provide unique stability, brightness, and multiplexed capacity for biomarker detection in complex diseases; however, their distinctive intracellular distribution has rarely been leveraged for spatially resolved diagnostics. Here, we show how QD-based sensors enable selective detection of cytoplasmic proteins and can quantify nucleo-cytoplasm protein mislocalization in patient-derived samples. We validated this approach labeling TAR DNA-binding protein 43 (TDP-43), a key mislocalized protein in amyotrophic lateral sclerosis (ALS). Spatial resolution is achieved in several patient-derived models and mouse brain tissue, underscoring the nanosensor's versatility across biological systems. Multiplexed QD-based immunolabeling, combined with confocal imaging and high-throughput flow cytometry, enables the detection of distinct cytoplasmic biomarker signatures that discriminate ALS patients from healthy controls. These signatures include variations in TDP-43 mislocalization and protein coexpression patterns, which were further modulated by pharmacological treatment. This work establishes QDs as spatially selective, multiplexable nanosensors capable of resolving subtle yet disease-relevant intracellular phenotypes in patient-derived samples. Compared to organic fluorophores, QDs enhance sensitivity, improve signal stability, and enable simultaneous spatially resolved biomarker quantification, broadening their potential for clinical diagnostics and personalized medicine. These findings establish QDs as powerful tools for neurodegeneration research, disease monitoring, and early biomarker discovery, with potential applications in translational neuroscience and precision medicine., Peer reviewed, Modelo experimental animal